News
PTGX
--
0.00%
--
US Thalassemia Treatment Market Size, Share, Global Industry Analysis, Revenue, Trend And Top Growing Companies to 2027
Jan 22, 2021 (Heraldkeepers) -- Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy...
Heraldkeepers · 4d ago
Hepcidin Market Peak Countries in the world 2021 Analysis by Industry Trends, Size, Share, Company Overview, Growth, Development and Forecast by 2025
Jan 11, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on the Hepcidin industry.” Global "Hepcidin Market” report...
The Express Wire · 01/11 05:12
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their Holdings
Simply Wall St. · 01/07 09:18
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
, /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that , Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on , at 2:00 p.m EST.
PR Newswire - PRF · 01/04 12:00
MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zacks · 12/29/2020 13:53
Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235
Zacks · 12/17/2020 14:36
Dosing underway in Protagonist Therapeutics' early stage study with PN-235
Protagonist Therapeutics (PTGX) has dosed the first subject in a Phase 1 study evaluating PN-235 (JNJ-77242113), an oral interleukin-23 receptor antagonist peptide. The study is designed to determine the safety,
Seekingalpha · 12/16/2020 12:44
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
, /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77242113), an oral interleukin-23 receptor (IL-23R) antagonist peptide. The study is ...
PR Newswire - PRF · 12/16/2020 12:30
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77242113), an oral interleukin-23 receptor (IL-23R) antagonist peptide. The study is designed to determi...
PR Newswire · 12/16/2020 12:30
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
, /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,476,189 shares of its common stock, including 714,285 sh...
PR Newswire - PRF · 12/15/2020 21:30
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire · 12/15/2020 21:30
Is PTGX A Good Stock To Buy Now?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the third qua...
Insider Monkey · 12/13/2020 13:37
Protagonist Therapeutics prices $100M stock offering
Protagonist Therapeutics (PTGX) has priced its public offering of 4,761,904 common shares at $21.00/share, for expected gross proceeds of $100M.Underwriters' over-allotment is an additional 714,285 shares.Closing date is December 15.Shares down
Seekingalpha · 12/11/2020 04:26
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
, /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 4,761,904 shares of its common stock at a price to the pub...
PR Newswire - PRF · 12/11/2020 04:10
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 4,761,904 shares of its common stock at a price to the public of $21.00 per s...
PR Newswire · 12/11/2020 04:10
Protagonist therapeutics readies equity offering
Protagonist Therapeutics (PTGX) has launched an underwritten public offering of $100M common shares.Underwriters have a 30-day option to purchase up to an additional 15% of the number of shares of
Seekingalpha · 12/10/2020 12:35
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
, /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of of shares of its common stock. All of the shares of common stock are being offered by Protagonist. In connection with this offering, Protagonist expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.
PR Newswire - PRF · 12/10/2020 12:30
Polycythemia Vera Pipeline Report presents an Updated Clinical Data of all the companies working in the Polycythemia Vera drug development scenario.
Polycythemia Vera Pipeline Report presents an Updated Clinical Data of all the companies working in the Polycythemia Vera drug development scenario.
GlobeNewswire · 12/09/2020 13:20
Protagonist Therapeutics called a ASH standout by BMO Capital
BMO Capital Markets is very positive on the update from Protagonist Therapeutics ([[PTGX]] +2.8%) at the ASH Conference. "We reiterate our Outperform rating on PTGX shares and increase our target
Seekingalpha · 12/07/2020 16:22
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
, /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the results of a large-scale analysis of real world treatment patterns for polycythemia vera, demonstrating that treatment incorporating existing options failed to achieve hematocrit control for a majority of patients and across broad categories of patient groups over the course of two years of observations. The analysis included patients in both high risk and low risk groups, as well as patients receiving phlebotomy alone or phlebotomy as a component of combination treatment. Details will be presented today at the American Society for Hematology (ASH) 2020 annual meeting.
PR Newswire - PRF · 12/07/2020 15:00
Webull provides a variety of real-time PTGX stock news. You can receive the latest news about Protagonist through multiple platforms. This information may help you make smarter investment decisions.
About PTGX
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.